You may notice: Thinking about food less often Stopping eating earlier Making different choices with less effort These are meaningful changes, even if weight loss is not immediate
A 2006 Child Neurology study noted reduced epilepsy seizures with L-Carnitine, indicating potential therapeutic use
In Europe, the European Medicines Agency (EMA) has initiated reviews to further examine whether drugs like semaglutide may increase risk for depression or other mood-related side effects
It was approved by the US Food and Drug Administration (FDA) on 1 April 2026 and is the second oral GLP-1 weight loss treatment to receive FDA approval, following the Wegovy tablet (oral semaglutide) in December 2025
Youve likely heard their names in the news or on social media: Ozempic, Wegovy, and the newest contender, Zepbound (Tirzepatide)
The first few weeks at each new dose level are when side effects are most intense your body is adjusting to a higher concentration of the drug